Brief: Ultragenyx Announces Positive Longer-Term Data From Phase 3 Study Of Dtx401 Aav Gene Therapy For The Treatment Of Glycogen Storage Disease Type Ia (Gsdia)
08/09/2025 21:45
Sept 8 (Reuters) - Ultragenyx Pharmaceutical Inc RARE.O: ULTRAGENYX ANNOUNCES POSITIVE LONGER-TERM DATA FROM PHASE 3 STUDY OF DTX401 AAV GENE THERAPY FOR THE TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE IA (GSDIA) ULTRAGENYX PHARMACEUTICAL INC - DTX401 WAS WELL TOLERATED WITH AN ACCEPTABLE SAFETY PROFILE ULTRAGENYX PHARMACEUTICAL INC - STUDY MET PRIMARY ENDPOINT WITH 41% CORNSTARCH REDUCTION Source text: ID:nGNX8zwwM1 Further company coverage: RARE.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ultragenyx Pharmaceutical
See all newsBrief: Ultragenyx Pharmaceutical Enters Settlement Agreement With Navinta On Dojolvi Patent Litigation - SEC Filing
Ultragenyx gains on $210 million US FDA voucher sale
Brief: Ultragenyx Pharmaceutical - Under Deal With U.S. Department Of Health Co To Pay 20% Of Prv Sale Proceeds To Nih
Brief: Ultragenyx Enters Into Agreement To Sell Rare Pediatric Disease Priority Review Voucher For $210 Million
U.S. STOCKS ON THE MOVE-CoreWeave, StubHub, Ultragenyx